These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 498294)

  • 41. [Quantitative assay of fibrinogen and fibrin grafts. Simple radial immunodiffusion and electroimmunoassay (author's transl)].
    Blatný J; Rozprínová L; Fiserová E; Frágner J
    Cas Lek Cesk; 1976 Jul; 115(28):861-4. PubMed ID: 821614
    [No Abstract]   [Full Text] [Related]  

  • 42. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
    Schwarz HP; Aiginger P; Kuzmits R
    Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Coagulant and procoagulant factors in ascitic fluid--about etiology DIC induced by ascitic fluid infusion (author's transl)].
    Ojiro M
    Igaku Kenkyu; 1981 Oct; 51(4):177-85. PubMed ID: 7331734
    [No Abstract]   [Full Text] [Related]  

  • 44. [A new method for measuring platelet fibrinogen levels by the use of the FDP-kit (author's transl)].
    Endo Y; Takahashi K; Shibata A
    Rinsho Ketsueki; 1976 Sep; 17(9):952-5. PubMed ID: 1034754
    [No Abstract]   [Full Text] [Related]  

  • 45. [Alterations in fibrinolytic activity in 94 cases of oral surgery. Influence of stress (author's transl)].
    Saulnier J; Conard J; Horellou MH; Schuhmann C; Samama M
    Ann Chir; 1980 Apr; 34(4):290-6. PubMed ID: 6446255
    [No Abstract]   [Full Text] [Related]  

  • 46. [Possibilities of using immunoenzyme test systems for determining levels of myoglobin, fibrinogen, fibrin-fibrinogen degradation products and fibronectin in the diagnosis of somatic diseases].
    Ermolin GA; Shelepova TM; Dikov MM; Osmanov SK; Voloshchuk OM
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):33-7. PubMed ID: 3300700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fibrinogen/fibrin degradation products in the toxemic patient].
    Ahued Ahued JR; Gaviño Ambriz S; Gaviño Gaviño F; Terán Ortiz LM
    Ginecol Obstet Mex; 1985 Apr; 53(336):83-6. PubMed ID: 4029682
    [No Abstract]   [Full Text] [Related]  

  • 48. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
    Klingemann HG; Brunswig D; Liehr H
    Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The coagulation system in Rivanol-induced abortion (author's transl)].
    Olund A; Bistoletti P
    Zentralbl Gynakol; 1980; 102(9):507-12. PubMed ID: 6781170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Determination of fibrinogen/fibrin degradation products for diagnostic purposes in internal diseases].
    Iwańska J; Donicowa K; Barańska H; Jarczewski J
    Pol Tyg Lek; 1977 Jun; 32(26):993-6. PubMed ID: 882451
    [No Abstract]   [Full Text] [Related]  

  • 51. [FFDP (fibrin fibrinogen degradation products), D-dimers, and SFMC (soluble fibrin monomer complex)].
    Kuroso K
    Rinsho Byori; 1987 Apr; Spec No 70():224-32. PubMed ID: 3302392
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effect of fibrin degradation products on different biological tests (author's transl)].
    Vila V; Aznar J; Regañon E
    Sangre (Barc); 1976; 21(4):814-26. PubMed ID: 1006498
    [No Abstract]   [Full Text] [Related]  

  • 53. Significance of fibrin-degradation products (F.D.P.) determinations in human glomerulopathies.
    Dewan R; Ahooja P; Rizvi SN; Gulati PD
    J Assoc Physicians India; 1978 Jul; 26(7):605-12. PubMed ID: 721767
    [No Abstract]   [Full Text] [Related]  

  • 54. Fibrin-fibrinogen degradation products in hepatic cirrhosis.
    Bulajić M; Kovacević N; Lalić M; Rolović Z
    Acta Med Iugosl; 1977; 31(4):333-8. PubMed ID: 596236
    [No Abstract]   [Full Text] [Related]  

  • 55. Fibrinogen degradation products in fresh frozen plasma. Possible contribution to immunosuppression.
    Donnell CA; Daniel SJ; Ferrara JJ
    Am Surg; 1989 Aug; 55(8):505-7. PubMed ID: 2764399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Determination of blood fibrinogen (fibrin) degradation products by reaction to hemagglutination delay of sensitized erythrocytes].
    Ponizovskiĭ MP; Tsynkalovskaia SN
    Vrach Delo; 1976 Aug; (8):115-7. PubMed ID: 1020269
    [No Abstract]   [Full Text] [Related]  

  • 57. [Serum levels of a immunosuppressive acidic protein in patients with gynecological cancer (author's transl)].
    Suzuki H; Miyoshi T; Sasaki H; Yoshida T
    Acta Obstet Gynaecol Jpn; 1981 Apr; 33(4):513-8. PubMed ID: 6785990
    [No Abstract]   [Full Text] [Related]  

  • 58. [Fibrinogen-fibrin degradation products in diabetes mellitus].
    Alakhverdian R; Koev D
    Vutr Boles; 1987; 26(6):72-5. PubMed ID: 3125689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significance of increased fibrin/fibrinogen degradation products and presence of fibrin monomers in pregnant women.
    Svanberg L; Eydal A; Astedt B
    Ann Chir Gynaecol Suppl; 1977; 66(5):247-50. PubMed ID: 596808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The causes of death in women suffering from advanced gynecological malignant tumours (author's transl)].
    Dvorák V; Bártová D; Mensík J
    Cesk Gynekol; 1977 May; 42(4):276-81. PubMed ID: 862057
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.